The endocannabinoid system in neuropathological states

References

• Aisen PS. The potential of anti-inflammatory drugs for the treatment of Alzheimer's disease. Lancet Neurology 2002; 1: 279–284
   PubMed Web of Science ®Google Scholar
• Allam MF, Del Castillo AS, Navajas RF. Parkinson's disease risk factors: Genetic, environmental, or both?. Neurological Research 2005; 27: 206–208
   PubMed Web of Science ®Google Scholar
• Alvarez FJ, Lafuente H, Rey-Santano MC, Mielgo VE, Gastiasoro E, Rueda M, et al. Neuroprotective effects of the non-psychoactive cannabinoid cannabidiol in hypoxic-ischemic newborn piglets. Pediatric Research 2008; 64: 653–658
   PubMed Web of Science ®Google Scholar
• Benito C, Romero JP, Tolón RM, Clemente D, Docagne F, Hillard CJ, et al. Cannabinoid CB1 and CB2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis. Journal of Neuroscience 2007; 27: 2396–2402
   PubMed Web of Science ®Google Scholar
• Benito C, Tolón RM, Pazos MR, Núñez E, Castillo AI, Romero J. Cannabinoid CB2 receptors in human brain inflammation. British Journal of Pharmacology 2008; 153: 277–285
   PubMedGoogle Scholar
• Carlsson A. Treatment of Parkinson's with L-DOPA. The early discovery phase, and a comment on current problems. Journal of Neural Transmission 2002; 109: 777–787
   PubMed Web of Science ®Google Scholar
• Carroll CB, Bain PG, Teare L, Liu X, Joint C, Wroath C, et al. Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study. Neurology 2004; 63(7)1245–1250
   PubMed Web of Science ®Google Scholar
• Citron M. Strategies for disease modification in Alzheimer's disease. Nature Review in Neurosciences 2004; 5: 677–685
   PubMed Web of Science ®Google Scholar
• Dickson DW. The pathogenesis of senile plaques. Journal of Neuropathol Exp Neurol 1997; 56: 321–339
   PubMed Web of Science ®Google Scholar
• Di Monte DA. The environment and Parkinson's disease: Is the nigrostriatal system preferentially targeted by neurotoxins?. Lancet Neurology 2003; 2: 531–538
   PubMed Web of Science ®Google Scholar
• Ehrhart J, Obregon D, Mori T, Hou H, Sun N, Bai Y, et al. Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation. Journal of Neuroinflammation 2005; 2: 29–39
   PubMed Web of Science ®Google Scholar
• Esposito E, Di Matteo V, Di Giovanni G. Death in the substantia nigra: A motor tragedy. Expert Review in Neurology 2007a; 7: 677–697
   PubMedGoogle Scholar
• Esposito G, Scuderi C, Savani C, Steardo L, De Filippis D, Cottone P, et al. Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression. British Journal of Pharmacology 2007b; 151: 1272–1279
   PubMed Web of Science ®Google Scholar
• Eubanks LM, Rogers CJ, Beuscher AE, Koob GF, Olson AJ, Dickerson TJ, et al. A molecular link between the active component of marijuana and Alzheimer's disease pathology. Molecular Pharmacology 2006; 3: 773–777
   PubMed Web of Science ®Google Scholar
• Farrer MJ. Genetics of Parkinson disease: Paradigm shifts and future prospects. Nature Reviews in Genetics 2006; 7: 306–318
   PubMed Web of Science ®Google Scholar
• Fernandez-Lopez D, Martinez-Orgado J, Nunez E, Romero J, Lorenzo P, Moro MA, et al. Characterization of the neuroprotective effect of the cannabinoid agonist WIN-55212 in an in vitro model of hypoxic-ischemic brain damage in newborn rats. Pediatric Research 2006; 60: 169–173
   PubMed Web of Science ®Google Scholar
• Fernandez-Lopez D, Pazos MR, Tolon RM, Moro MA, Romero J, Lizasoain I, et al. The cannabinoid agonist WIN55212 reduces brain damage in an in vivo model of hypoxic-ischemic encephalopathy in newborn rats. Pediatriac Research 2007; 62: 255–260
   PubMedGoogle Scholar
• Fernandez-Ruiz JJ, Gonzalez S, Romero J, Ramos JA. Cannabinoids in neurodegeneration and neuroprotection. Cannabinoids as therapeutics, R Mechoulam. Birkhäuser Verlag, BaselSwitzerland 2005; 79–109
   Google Scholar
• Franklin A, Stella N. Arachidonylcyclopropylamide increases microglial cell migration through cannabinoid CB2 and abnormal-cannabidiol-sensitive receptors. European Journal of Pharmacology 2003; 474: 195–198
   PubMed Web of Science ®Google Scholar
• Galve-Roperh I, Aguado T, Palazuelos J, Guzmán M. The endocannabinoid system and neurogenesis in health and disease. Neuroscientist 2007; 13: 109–114
   PubMedGoogle Scholar
• García-Arencibia M, García C, Kurz A, Rodríguez-Navarro JA, Gispert-Sánchez S, Mena MA, et al. Cannabinoid CB1 receptors are early down-regulated followed by a further up-regulation in the basal ganglia of mice with deletion of specific PARK genes. Journal of Neural Transmission 2009, (in press)
   Google Scholar
• García-Arencibia M, García C, Fernández-Ruiz J. Cannabinoids and Parkinson's disease. Current Drug Targets – CNS and Neurological Disorders 2009, (in press)
   Google Scholar
• García-Arencibia M, González S, de Lago E, Ramos JA, Mechoulam R, Fernández-Ruiz J. Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: Importance of antioxidant and cannabinoid receptor-independent properties. Brain Research 2007; 1134: 162–170
   PubMed Web of Science ®Google Scholar
• Glass M, Faull RLM, Dragunow M. Loss of cannabinoid receptors in the substantia nigra in Huntington's disease. Neuroscience 1993; 56: 523–527
   PubMed Web of Science ®Google Scholar
• Griffin WS. Inflammation and neurodegenerative diseases. American Journal of Clinical Nutrition 2006; 83: 470S–474S
   PubMed Web of Science ®Google Scholar
• Hajos N, Ledent C, Freund TF. Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. Neuroscience 2001; 106: 1–4
   PubMed Web of Science ®Google Scholar
• Hampson AJ, Grimaldi M, Axelrod J, Wink D. Cannabidiol and (-)Δ9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci USA 1998; 95: 8268–8273
   PubMed Web of Science ®Google Scholar
• Hansen HH, Schmid PC, Bittigau P, Lastres-Becker I, Berrendero F, Manzanares J, et al. Anandamide, but not 2-arachidonoylglycerol, accumulates during in vivo neurodegeneration. Journal of Neurochemistry 2001; 78: 1415–1427
   PubMed Web of Science ®Google Scholar
• Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacological Reviews 2002; 54: 161–202
   PubMed Web of Science ®Google Scholar
• Howlett AC, Breivogel C, Childers SR, Deadwyler SA, Hampson RE, Porrino LJ. Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology 2004; 47: 345–358
   PubMed Web of Science ®Google Scholar
• Jiménez-del-Río M, Daza-Restrepo A, Velez-Pardo C. The cannabinoid CP55,940 prolongs survival and improves locomotor activity in Drosophila melanogaster against paraquat: Implications in Parkinson's disease. Neuroscience Research 2008; 61: 404–411
   PubMedGoogle Scholar
• Jin KL, Mao XO, Goldsmith PC, Greenberg DA. CB1 cannabinoid receptor induction in experimental stroke. Annals in Neurology 2000; 48: 257–261
   PubMed Web of Science ®Google Scholar
• Knoller N, Levi L, Shoshan I, Reichental E, Razon N, Rappaport ZH, et al. Dexanabinol (HU-211) in the treatment of severe closed head injury: A randomized, placebo-controlled, phase II clinical trial. Crit Care Med 2002; 30: 548–554
   PubMed Web of Science ®Google Scholar
• Lastres-Becker I, Cebeira M, de Ceballos M, Zeng BY, Jenner P, Ramos JA, et al. Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets. European Journal of Neuroscience 2001; 14: 1827–1832
   PubMed Web of Science ®Google Scholar
• Lastres-Becker I, Molina-Holgado F, Ramos JA, Mechoulam R, Fernández-Ruiz J. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: Relevance to Parkinson's disease. Neurobiology of Disease 2005; 19: 96–107
   PubMed Web of Science ®Google Scholar
• Lipton SA. Failures and successes of NMDA receptor antagonists: Molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults. Neuroradiology 2004; 1: 101–110
   Google Scholar
• Lleó A, Greenberg SM, Growdon JH. Current pharmacotherapy for Alzheimer's disease. Annual Review in Medicine 2006; 57: 513–533
   PubMed Web of Science ®Google Scholar
• Maas AIR, Murray G, Henney H, III, Kassem N, Legrand V, Mangelus M, et al. Efficacy and safety of dexanabinol in severe traumatic brain injury: Results of a phase III randomised, placebo-controlled, clinical trial. Lancet Neurology 2006; 5: 38–45
   PubMed Web of Science ®Google Scholar
• Maresz K, Carrier EJ, Ponomarev ED, Hillard CJ, Dittel BN. Modulation of the cannabinoid CB receptor in microglial cells in response to inflammatory stimuli. Journal of Neurochemistry 2005; 95: 437–445
   PubMed Web of Science ®Google Scholar
• Martinez-Orgado J, Fernandez-Frutos B, Gonzalez R, Romero E, Uriguen L, Romero J, et al. Neuroprotection by the cannabinoid agonist WIN-55212 in an in vivo newborn rat model of acute severe asphyxia. Molecular Brain Research 2003; 114: 132–139
   PubMedGoogle Scholar
• Martínez-Orgado J, Fernández-López D, Lizasoain I, Romero J. The seek of neuroprotection: Introducing cannabinoids. Recent Patents CNS Drug Discovery 2007; 2: 131–139
   PubMedGoogle Scholar
• Meyer-Luehmann M, Spires-Jones TL, Prada C, Garcia-Alloza M, de Calignon A, Rozkalne A, et al. Rapid appearance and local toxicity of amyloid-plaques in a mouse model of Alzheimer´s disease. Nature 2008; 451: 720–725
   PubMed Web of Science ®Google Scholar
• Molina-Holgado F, Pinteaux E, Moore JD, Molina-Holgado E, Guaza C, Gibson RM, et al. Endogenous interleukin-1 receptor antagonist mediates anti-inflammatory and neuroprotective actions of cannabinoids in neurons and glia. Journal of Neuroscience 2003; 23(16)6470–6474
   PubMed Web of Science ®Google Scholar
• Nadler V, Biegon A, Beit-Yannai E, Adamchik J, Shohami E. 45Ca accumulation in rat brain after closed head injury; Attenuation by the novel neuroprotective agent HU-211. Brain Research 1995; 685: 1–11
   PubMed Web of Science ®Google Scholar
• Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: A case report. Nature Medicine 2003; 9: 448–452
   PubMed Web of Science ®Google Scholar
• Olanow CW. The pathogenesis of cell death in Parkinson's disease – 2007. Movement Disorders 2007; Supplementum 17: S335–S342
   Google Scholar
• Passmore MJ. The cannabinoid receptor agonist nabilone for the treatment of dementia-related agitation. International Journal of Geriatric Psychiatry 2008; 23: 116–117
   PubMed Web of Science ®Google Scholar
• Pisani A, Fezza F, Galati S, Battista N, Napolitano S, Finazzi-Agro A, et al. High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson's disease patients. Annals in Neurology 2005; 57: 777–7779
   PubMed Web of Science ®Google Scholar
• Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K, et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nature Medicine 2007; 13: 1359–1362
   PubMed Web of Science ®Google Scholar
• Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Möbius HJ, et al. Memantine in moderate-to-severe Alzheimer's disease. New England Journal of Medicine 2003; 348: 1333–1341
   PubMed Web of Science ®Google Scholar
• Sagredo O, García-Arencibia M, de Lago E, Finetti S, Decio A, Fernández-Ruiz J. Cannabinoids and neuroprotection in basal ganglia disorders. Molecular Neurobiology 2007a; 36: 82–91
   PubMed Web of Science ®Google Scholar
• Sagredo O, Ramos JA, Decio A, Mechoulam R, Fernández-Ruiz J. Cannabidiol reduced the striatal atrophy caused by 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors. European Journal of Neuroscience 2007b; 26: 843–851
   PubMed Web of Science ®Google Scholar
• Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, et al. Immunization wih amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999; 400: 173–177
   PubMed Web of Science ®Google Scholar
• Sethi KD. Clinical aspects of Parkinson disease. Current Opinion in Neurology 2002; 15: 457–460
   PubMed Web of Science ®Google Scholar
• Sieradzan KA, Fox SH, Hill M, Dick JP, Crossman AR, Brotchie JM. Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: A pilot study. Neurology 2001; 57: 2108–2111
   PubMed Web of Science ®Google Scholar
• Streit WJ. Microglia and neuroprotection: Implications for Alzheimer´s disease. Brain Research Reviews 2005; 48: 234–239
   PubMedGoogle Scholar
• Venderová K, Růzicka E, Vorísek V, Visnovský P. Survey on cannabis use in Parkinson's disease: Subjective improvement of motor symptoms. Movement Disorders 2004; 19: 1102–1106
   PubMed Web of Science ®Google Scholar
• Volicer L, Stelly M, Morris J, McLaughlin J, Volicer BJ. Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease. International Journal of Geriatric Psychiatry 1997; 12: 913–919
   PubMed Web of Science ®Google Scholar
• Volpe JJ. Hypoxic – ischemic encephalopathy: Clinical aspects. Neurology of the newborn, JJ Volpe. WB Saunders, Philadelphia 2001; 331–394
   Google Scholar
• Walsh DM, Selkoe DJ. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 2004; 44: 181–193
   PubMed Web of Science ®Google Scholar
• Walther S, Mahlberg R, Eichmann U, Kunz D. Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia. Psychopharmacology 2006; 185: 524–528
   PubMed Web of Science ®Google Scholar
• Wimo A, Winblad B, Agüero Torres H, von Strauss E. The magnitude of dementia occurrence in the world. Alzheimer Disease and Associated Disorders 2003; 17: 63–67
   PubMed Web of Science ®Google Scholar
• Wyss-Coray T. Inflammation in Alzheimer disease: Driving force, bystander or beneficial response?. Nature Medicine 2006; 12: 1005–1015
   PubMed Web of Science ®Google Scholar
• Zdanys K, Tampi RR. A systematic review of off-label uses of memantine for psychiatric disorders. Progress in Neuropsychopharmacology and Biological Psychiatry 2008; 32: 1362–74
   PubMedGoogle Scholar
• Zhang M, Martin BR, Adler MW, Razdan RK, Ganea D, Tuma RF. Modulation of the balance between cannabinoid CB1 and CB2 receptor activation during cerebral ischemic/reperfusion injury. Neuroscience 2008; 152: 753–760
   PubMedGoogle Scholar
• Zygmunt PM, Petersson J, Andersson DA, Chuang H, Sorgard M, Di Marzo V, et al. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 1999; 400: 452–457
   PubMed Web of Science ®Google Scholar